前列腺癌治疗市场基于(关键地区、市场参与者、规模和份额)- 到 2030 年的预测

  • Report Code : TIPRE00003423
  • Category : Pharmaceuticals
  • Status : Data Released
  • No. of Pages : 150
Buy Now

【研究报告】前列腺癌治疗市场预计将从2022年的147.6773亿美元增长到2030年的284.2527亿美元;预计从 2022 年到 2030 年,复合年增长率将达到 8.5%。
市场洞察和分析师观点:
随着研发活动的不断增加,引入新的药物化合物,前列腺癌的数量不断增加,前列腺癌治疗市场规模正在扩大癌症病例以及政府对前列腺癌诊断的支持不断增加。此外,市场参与者提供先进产品也推动了市场增长。 2023年1月,BDR Pharmaceutical在印度推出了Apalutamide的仿制药,用于治疗前列腺癌。该药物以 APATIDE 品牌推出,用于治疗非转移性去势抵抗性前列腺癌和转移性去势敏感型前列腺癌。
增长动力和挑战:
前列腺癌是最常见的健康问题之一男性,尤其是 50 岁及以上的老年男性。前列腺癌最常见于肥胖且有前列腺癌家族史的男性。前列腺癌是一种无声的威胁,因为它通常在没有明显症状的情况下发展。因此,早期发现这种癌症并不那么容易。大多数前列腺癌起源于前列腺的周围区域。为了使症状变得明显,癌症必须达到对尿道施加压力的大小,否则在某些情况下,转移引起的骨痛可能是晚期前列腺癌的最初症状。然而,任何 50 岁或以上出现下尿路症状、勃起功能障碍或血尿的人都应考虑前列腺癌的可能性。前列腺癌是全球男性癌症死亡的第五大原因,也是第二大常见癌症。即使自2000年以来前列腺癌的发病率有所下降,但从2010年开始,晚期前列腺癌的发病率却有所上升。前列腺癌的发病率和死亡率差异很大。发达国家的前列腺癌发病率普遍较高,但死亡率较低。美国患前列腺癌的风险几乎是全球风险的四倍。据诺华公司称,2020 年,全球报告约 140 万新发前列腺癌病例,约 375,000 例前列腺癌死亡。全球前列腺癌病例数量不断增加以及前列腺癌的低检出率推动了前列腺癌治疗市场的增长。
战略见解
报告细分和范围:
前列腺癌治疗市场根据治疗进行细分类型、最终用户和地理位置。前列腺癌治疗市场按治疗类型分为激素治疗、化疗、免疫治疗、靶向治疗等。按最终用户划分,前列腺癌治疗市场分为医院、专科诊所等。根据地理位置,前列腺癌治疗市场分为北美(美国、加拿大和墨西哥)、欧洲(英国、德国、法国、意大利、西班牙和欧洲其他地区)、亚太地区(中国、日本) 、印度、韩国、澳大利亚和亚太地区其他地区)、中东和非洲(阿联酋、沙特阿拉伯、南非以及中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷) ,以及南美洲和中美洲其他地区)。
细分分析:
前列腺癌治疗市场按治疗类型分为激素治疗、化疗、免疫治疗、靶向治疗等。 2022年,激素治疗领域占据了仅次于化疗的最大市场份额,预计2022年至2030年该领域将创下最高复合年增长率。化疗被认为是前列腺癌的重要治疗方法。在这种疗法中,药物会破坏肺部新的或现有的癌细胞。转移性前列腺癌的化疗可以缓解症状。它还可以帮助减少癌症并提高生活质量。多西紫杉醇(泰索帝)被认为是对激素治疗耐药的前列腺癌化疗患者的标准治疗方法。 FDA 还批准了化疗药物卡巴他赛(Jevtana)用于治疗去势抵抗性前列腺癌。它还用于患有在服用多西紫杉醇时生长的转移性前列腺癌的患者。
前列腺癌治疗市场,按最终用户划分 - 2022 年和 2030 年
区域分析:
前列腺癌治疗市场按地理位置划分北美、欧洲、亚太地区、中东和非洲、以及南美洲和中美洲。北美是全球前列腺癌治疗市场增长的最大贡献者。预计2022年至2030年,亚太地区前列腺癌治疗市场的复合年增长率最高。美国前列腺癌治疗市场的增长主要由前列腺癌病例发病率的增加、产品发布和政府举措推动。 2023年6月,阿斯利康和默沙东的Lynparza(olaparib)联合泼尼松或泼尼松龙和阿比特龙在美国被批准用于治疗疑似有害BRCA突变(BRCAm)转移性去势抵抗性前列腺癌(mCRPC)的成年患者。此外,2023年11月,FDA批准了Astellas Pharma US, Inc.生产的产品enzalutamide。该产品用于治疗生化复发且转移风险高的非转移性去势敏感型前列腺癌 (nmCSPC)(高风险 BCR)。
行业发展和未来机遇:
关键的各种举措前列腺癌治疗市场的参与者如下:
2022 年 3 月,美国 FDA 批准诺华的 Pluvicto(镥 Lu 177 vipivotide tetraxetan)用于治疗患有一种称为前列腺特异性膜抗原的晚期前列腺癌的成年患者 -阳性转移性去势抵抗性前列腺癌(PSMA 阳性 mCRPC)。 2023年4月,FDA授予Lantheus Holdings Inc和POINT Biopharma Global Inc用于治疗转移性去势抵抗性前列腺癌(mCRPC)的177Lu-PNT2002快速通道资格。 PNT2002 是一种创新的 PSMA 靶向 177Lu 放射性药物疗法,结合了 PSMA 靶向配体、PSMA-I&T 和 β 发射放射性同位素无载体添加 177Lu,用于治疗 mCRPC。竞争格局和主要公司:
Astella Pharma Inc 、强生服务公司、礼来公司、拜耳公司、赛诺菲公司、默克公司、阿斯利康公司、诺华公司、艾伯维公司和百时美施贵宝公司都是前列腺癌治疗市场的知名参与者。这些市场参与者专注于新产品的推出和地域扩张,以满足全球不断增长的消费者需求,并增加其专业产品组合的产品范围。他们的全球业务使他们能够为大量客户提供服务,从而促进市场扩张。
Report Coverage
Report Coverage

Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends

Segment Covered
Segment Covered

This text is related
to segments covered.

Regional Scope
Regional Scope

North America, Europe, Asia Pacific, Middle East & Africa, South & Central America

Country Scope
Country Scope

This text is related
to country scope.

Frequently Asked Questions


What are prostate cancer therapeutics?

Prostate cancer is one of the most common health problems in men, especially in older men (aged above 50 years). Prostate cancer is mostly common in men who are obese and have a family history of prostate cancer. Prostate cancer is a silent threat that often develops without noticeable symptoms, and hence, early detection of this cancer is not that easy. Typically, the majority of prostate cancers originate in the peripheral region of the prostate gland. Consequently, for symptoms to become apparent, the cancer must reach a size where it exerts pressure on the urethra, or in some cases, bone pain from the metastasis might be the initial presenting symptom of advanced prostate cancer. However, any individual aged 50 or above who presents with lower urinary tract symptoms, erectile dysfunction, or hematuria should consider the possibility of prostate cancer.

What are the driving and restraining factors for the prostate cancer therapeutics market?

The increasing cases of prostate cancer and strategic initiatives in prostate cancer therapeutics freezer bolster the prostate cancer therapeutics market size. However, the high cost associated with prostate cancer therapeutics hinders the growth of prostate cancer therapeutics market growth.

Who are the major players in the market the prostate cancer therapeutics market?

The prostate cancer therapeutics market majorly consists of players such Astella Pharma Inc, Johnson & Johnson Services Inc, Eli Lilly and Company, Bayer AG, Sanofi, Merck KGaA, AstraZeneca, Novartis AG, AbbVie, and Bristol Myers Squibb

Which segment is dominating the prostate cancer therapeutics market?

The prostate cancer therapeutics market, by therapy type, is segmented into hormone therapy, chemotherapy, immunotherapy, targeted therapy, and others. In 2022, the chemotherapy segment held the largest market share, and the same segment is expected to record the highest CAGR from 2022 to 2030.
The prostate cancer therapeutics market, by end-user, is segmented into hospitals, specialty clinics, and others. In 2022, the hospital segment held the largest market share; moreover, the same segment is expected to record the highest CAGR during 2022–2030.

Which region is dominating the prostate cancer therapeutics market?

Based on geography, the prostate cancer therapeutics market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and Rest of the Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America). North America is the largest contributor to global prostate cancer therapeutics market growth. Asia Pacific is expected to register the highest CAGR in the prostate cancer therapeutics market from 2022 to 2030.

The List of Companies - Prostate Cancer Market

  1. Astella Pharma Inc
  2. Johnson & Johnson Services Inc
  3. Eli Lilly, and Company
  4. Bayer AG
  5. Sanofi
  6. Merck KGaA
  7. AstraZeneca
  8. Novartis AG
  9. AbbVie
  10. Bristol Myers Squibb

The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.

  1. Data Collection and Secondary Research:

As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.

Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.

  1. Primary Research:

The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.

For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.

A typical research interview fulfils the following functions:

  • Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
  • Validates and strengthens in-house secondary research findings
  • Develops the analysis team’s expertise and market understanding

Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:

  • Industry participants: VPs, business development managers, market intelligence managers and national sales managers
  • Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.

Below is the breakup of our primary respondents by company, designation, and region:

Research Methodology

Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.

  1. Data Analysis:

Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.

  • Macro-Economic Factor Analysis:

We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.

  • Country Level Data:

Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.

  • Company Profile:

The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.

  • Developing Base Number:

Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.

  1. Data Triangulation and Final Review:

The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.

We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.

We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.

Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Related Reports